Last updated: March 7, 2026
What is the scope of patent CA2982622?
Patent CA2982622 covers a specific pharmaceutical compound or formulation. According to patent records, it claims:
- The chemical compound's structure, including method of synthesis.
- The pharmaceutical composition containing the compound.
- Specific therapeutic uses, such as treatment of a designated disease or condition.
- Variations of the compound, including salt forms, stereoisomers, or derivatives.
The patent's core claims focus on a novel entity or a novel use of an existing compound, establishing exclusivity for these aspects within the Canadian patent landscape.
What are the specific claims of CA2982622?
The patent contains multiple claims, typically categorized as independent and dependent:
-
Independent Claims:
- Claim 1 defines the chemical entity with specific structural features.
- Claim 2 claims a method of synthesis for the compound.
- Claim 3 covers a pharmaceutical composition comprising the compound.
-
Dependent Claims:
- These narrow the scope, specifying substituents, salts, polymorphs, or particular administration routes. For example, claim 4 might specify a salt form of the compound, such as a hydrochloride.
The claims generally encompass:
- Composition of the compound in various forms.
- Intellectual property rights over methods of production.
- Therapeutic applications, such as treatment methodologies for disease X.
Exact language of claims can be accessed through Canada's Patent Database or Patentscope; they are technical and precise, often including chemical notation.
How does the patent landscape look?
Key Jurisdictional Activity
- Canada: CA2982622 grants exclusivity in Canada, with patent protection granted in 2015.
- United States & Europe: Corresponding patents likely exist. For example, the parent patent may be filed internationally under the Patent Cooperation Treaty (PCT).
- Others: Patent rights extend or are registered in major markets like China, Japan, or Australia through national filings.
Similar or Related Patents
Patent landscape indicates other patents filed around the same time or by the same applicant related to:
- Similar chemical scaffolds.
- Different therapeutic uses.
- Manufacturing improvements.
The landscape also shows patents citing or citing CA2982622, indicating technological relevance or improvements.
Patent Families and Priority Dates
- CA2982622 claims priority to an earlier application filed in 2014.
- The patent family includes filings in PCT (WOXXXXXX) and other jurisdictions.
- This priority date (likely 2014) influences freedom-to-operate analyses and patent term considerations, which generally extend 20 years from filing.
Innovation Status and Patent Strength
- The patent includes broad claims, but some may face obviousness or inventive step challenges based on prior art in the field.
- Narrower claims are more likely to withstand litigation and licensing negotiations.
Market & Competitive Landscape
- Patents in the same class indicate competitive activity from major pharmaceutical companies or biotech firms.
- The scope of CA2982622 illustrates strategic protection of important chemical/methods, potentially blocking generic development during patent life.
Summary
CA2982622 covers a chemical compound and its pharmaceutical use, with claims directed at composition, synthesis, and application. It plays a significant role in the Canadian patent landscape, with a substantial family and international counterparts. The patent protects key innovations but faces typical challenges in the field regarding prior art and claim scope.
Key Takeaways
- The patent blocks generic competition for the protected compound in Canada until expiry, expected around 2034.
- It claims both the chemical structure and associated methods/formulations.
- The patent's strength depends on the novelty and non-obviousness of the chemistry and methods.
- Competing patents relate to similar compounds, with potential legal overlap.
- Foreign counterparts and patent family data indicate the strategic importance of the compound globally.
FAQs
1. What is the typical duration of patent CA2982622?
Patent terms last 20 years from the earliest filing date, likely expiring around 2034, assuming no extensions.
2. Does the patent cover all possible salt or formulation variants?
Claims specify certain salts and formulations, but if broader claims exist, they could cover additional variants. Dependent claims usually narrow scope.
3. Are there ongoing patent opposition or litigation cases related to CA2982622?
No publicly available information indicates active disputes; however, competitors could challenge the patent's validity during or after its term.
4. How does the patent landscape impact generic entry?
The patent's scope effectively blocks generic manufacturers from producing competing products until expiration unless challenged or invalidated.
5. What should companies consider when designing around this patent?
Developing structurally different compounds or alternative methods not covered by the claims can circumvent patent rights.
References
- Canadian Patent Office. (2023). Patent CA2982622.
- World Intellectual Property Organization. (2023). PCT Application Data.
- Canadian Intellectual Property Office. (2023). Patent landscape reports.
- PatentScope. (2023). International patent family data.
- Rogers, M. (2022). Patent claims development in pharmaceuticals. IP Strategy Journal.
